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Abstract 
Background: Cape Verde is an archipelago located off the West African coast and is in a pre-elimination phase of 
malaria control. Since 2010, fewer than 20 Plasmodium falciparum malaria cases have been reported annually, except 
in 2017, when an outbreak in Praia before the rainy season led to 423 autochthonous cases. It is important to under-
stand the genetic diversity of circulating P. falciparum to inform on drug resistance, potential transmission networks 
and sources of infection, including parasite importation.
Methods: Enrolled subjects involved malaria patients admitted to Dr Agostinho Neto Hospital at Praia city, Santiago 
island, Cape Verde, between July and October 2017. Neighbours and family members of enrolled cases were assessed 
for the presence of anti-P. falciparum antibodies. Sanger sequencing and real-time PCR was used to identify SNPs in 
genes associated with drug resistance (e.g., pfdhfr, pfdhps, pfmdr1, pfk13, pfcrt), and whole genome sequencing data 
were generated to investigate the population structure of P. falciparum parasites.
Results: The study analysed 190 parasite samples, 187 indigenous and 3 from imported infections. Malaria cases 
were distributed throughout Praia city. There were no cases of severe malaria and all patients had an adequate clinical 
and parasitological response after treatment. Anti-P. falciparum antibodies were not detected in the 137 neighbours 
and family members tested. No mutations were detected in pfdhps. The triple mutation S108N/N51I/C59R in pfdhfr 
and the chloroquine-resistant CVIET haplotype in the pfcrt gene were detected in almost all samples. Variations in 
pfk13 were identified in only one sample (R645T, E668K). The haplotype NFD for pfmdr1 was detected in the majority 
of samples (89.7%).
Conclusions: Polymorphisms in pfk13 associated with artemisinin-based combination therapy (ACT) tolerance in 
Southeast Asia were not detected, but the majority of the tested samples carried the pfmdr1 haplotype NFD and 
anti-malarial-associated mutations in the the pfcrt and pfdhfr genes. The first whole genome sequencing (WGS) was 
performed for Cape Verdean parasites that showed that the samples cluster together, have a very high level of similar-
ity and are close to other parasites populations from West Africa.
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Background
Malaria, caused by Plasmodium parasites, is a global 
public health problem. Almost half of world popula-
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million cases and 405,000 deaths, globally [1]. In Africa, 
where Plasmodium falciparum infections dominate, 6 
countries (Nigeria, Democratic Republic of the Congo, 
Uganda, Côte d’Ivoire, Mozambique, Niger) accounted 
for more than half of all malaria cases worldwide. Fur-
ther, 94% of all malaria deaths occurred in the African 
continent. Due to malaria control activities, such as 
improved case management and roll-out of insecticide-
treated nets and indoor residual spraying, the num-
ber of countries moving towards disease elimination 
has increased. In particular, the number of countries 
with < 100 indigenous cases increased from 17 in 2010 
to 27 in 2018 [1].
Cape Verde (population size: ~ 500,000) is one of the 
African countries in a pre-elimination phase of malaria 
control, with < 1 case per 1000 population per year [2]. 
There were 583 indigenous cases and 5 deaths between 
2010 and 2018. However, in 2017, 423 (72.6%) cases 
occurred in an outbreak. This year was an outlier as it 
corresponds to an increase of 89.9% of cases compared 
to previous years, and excluding it, the number of cases 
reported yearly since 2010 has varied between 1 and 48 
(average < 20 cases) [1].
The research and studies conducted within the scope of 
this epidemic revealed that the probable factors associ-
ated with the increase in the number of cases were: (1) 
the reduction of indoor residual spraying; (2) the reduc-
tion of regular vector control interventions [3]; and, (3) 
ecological and environmental factors such as unusual 
high rainfall during 2016 [4]. In response to the 2017 
outbreack, authorities have implemented measures to 
improve vector control interventions, which has contrib-
uted to reducing autochthonous malaria cases and mor-
tality since 2018 [1, 4].
Despite the control efforts implemented by health 
authorities, autochthonous cases persist and could delay 
elimination targets. Malaria prevalence is unstable and 
autochthonous cases are restricted to the islands of 
Santiago (96%) and Boavista (4%), while imported cases 
from countries with disease transmission are recorded 
in all 9 islands. In recent years, local transmission has 
been restricted to the island of Santiago, especially in 
Praia city, capital of the country, where 158 cases were 
recorded, more than 90% of autochthonous cases from 
2010 to 2016 [2]. There is typically low malaria endemic-
ity, but there are fluctuations in morbidity depending on 
rainfall, with transmission normally occurring between 
the months of September and November [5]. However, 
in 2017, the malaria outbreak occurred before the rainy 
season, where all 423 autochthonous P. falciparum cases 
were reported in Praia city [3, 4]. Eighteen patients had 
at least two relapse episodes in that year, 23 further 
imported cases were registered [4].
All non-complicated malaria cases in Cape Verde are 
hospitalized and treated with artemisin-based combina-
tion therapy (ACT): artemether and lumefantrine, which 
targets the parasite erythrocytic asexual stage. All cases 
also receive the gametocytocidal primaquine drug at the 
start of treatment to prevent transmission and interrupt 
the spread of the disease. Severe cases are treated with 
intravenous artesunate. Levels of parasitaemia are moni-
tored at health facilities during the period of the disease 
and followed up on multiple occasions, up to 42 days [6]. 
Success in the control and treatment of malaria depends 
on the clinical efficiency of ACT and avoiding drug 
resistance [7]. Therefore, understanding the epidemiol-
ogy of drug resistance is vital for an effective drug policy, 
especially within the Cape Verde elimination settings [8].
The non-temporary movement of people between 
Cape Verde and malaria-endemic countries, particularly 
to and from West Africa, increases the potential for case 
importation, and poses a challenge to malaria elimina-
tion on the archipelago [9]. The circulation of parasites 
between regions also increases the risk of importing drug 
resistance, which is underpinned by mutations in the P. 
falciparum genome. For example, polymorphisms associ-
ated with resistance to several anti-malarial drugs have 
been identified in P. falciparum genes pfdhfr (target for 
anti-malaria drug pryrimethamine), pfdhps (target for 
sulfadoxine), pfcrt (target for chloroquine), pfk13 (tar-
get for artemisin) and pfmdr1 (target for mefloquine, 
chloroquine). Similarly, P. falciparum genetics (e.g., 
pfama1 gene) also gives the parasite the ability to evade 
the immune response of the host. Therefore, there is 
a need to understand the genetic diversity of circulat-
ing parasites to inform on drug resistance and trans-
mission networks identified by finding near-identical 
parasite genomic sequences. To support this, epidemio-
logical data and blood samples were collected from close 
contacts of patients, including neighbours and family 
members, thereby informing on potential risk factors 
for malaria susceptibility, transmission and the emer-
gence and spread of outbreaks. Further, this study on 
the molecular characterization of P. falciparum isolates 
collected from patients during the 2017 outbreak will 
provide a baseline assessment of malaria parasite drug 
resistance profile and genetics in Cape Verde, from which 
to design population-specific diagnostics, and contribute 
to strengthening the country’s measures for prevention 
and control, in order to achieve its elimination targets.
Methods
Malaria patients
Malaria patients admitted to Dr Agostinho Neto Hos-
pital at Praia city, Santiago island, Cape Verde, between 
July and October 2017 were enrolled. A total of 190 (from 
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446; 187 indigenous, 3 imported) gave informed consent 
to participate in the present study. The laboratory diag-
nosis of malaria was performed by rapid diagnostic tests 
and microscopy.
All 190 patients that agreed to participate remained 
hospitalized for at least 3 days and were discharged from 
hospital only after laboratory confirmation of Plasmo-
dium spp. negative blood smear and clinical evaluation; 
follow-up assessments were performed on days 7, 14, 21, 
28, 35, and 42 post-start of treatment. The management 
of participating patients strictly followed the guidelines 
from the Ministry of Health [6].
Data and sample collection
Data were obtained from laboratory analysis and from a 
questionnaire. Of the 190 malaria cases enrolled in this 
study, 131 (68.9%) cases and their neighbours and family 
members (n = 137; without malaria symptoms), answered 
a questionnaire in a community setting. This question-
naire was designed in both Portuguese and Crioulo, 
which captured sociodemographic data, present and past 
about malaria and fever, travel information and signs 
and symptoms consistent with malaria. Species identi-
fication and parasite quantification was performed by 
microscopic observations of thick and thin blood smears. 
Blood drops of malaria cases and their neighbours/fam-
ily obtained by finger prick were collected on filter paper 
and stored at − 20 °C for later molecular characterization 
of parasites and antibody (AMA1 and MSP1) detection. 
Parasite DNA was extracted using Chelex [10] and spe-
cies confirmation by PCR [11].
AMA1 and MSP1‑19 indirect ELISA
Dried blood spot elution was performed as previously 
described [12]. In brief, 137 blood spots from samples 
collected in 2017 were equilibrated to ambient room 
temperature before opening, and 2.5-mm diameter discs 
were cut from Whatman 3 MM paper using a leather 
punch. Each disc was then eluted in a 96-deep-well plate 
containing 150 μl PBS/0.05% (v/v) Tween 20/0.05% (w/v) 
sodium azide and incubated at ambient room tempera-
ture for > 18  h with gentle rotary agitation ~ 100  rpm. 
Serum was diluted to a 1:100 dilution. IgG antibodies 
were detected by indirect ELISA using MSP1-19 (Well-
come Genotype) and AMA1 (3D7) antigens expressed in 
Escherichia coli strain BL21, as described by Okech et al. 
[13], and by Hoder [14]. AMA1 and MSP1-19 antigens 
were coated onto 96-well ELISA plates (Immulon 4HBX, 
Thermo) with coating buffer (carbonate-bicarbonate) 
in a 50-µl volume at a concentration of 0.5  µg/m and 
incubated a 40  °C overnight. Plates were washed sev-
eral times using PBS plus 0.05% Tween 20 (PBS/T) and 
blocked with 1% (w/v) skimmed milk powder in PBS/T 
(block solution). The previously eluted serum was used 
at 1:400 working dilution into block solution. European 
confirmed negative and pooled hyperimmune positive 
serum were used as negative/positive control samples. 
Serum was incubated at 40˚C overnight and washed in 
PBS/T. Rabbit anti-human HRP conjugated secondary 
antibody (Dako) was used at a concentration of 1:15,000 
in PSB/T. TMB substrate was added followed by a 15-min 
room temperature (RT) incubation.  H2SO4 stop solution 
was added, followed by plate reading at 450 nm.
Candidate gene sequencing and analysis
A total of 38 samples with the highest parasitaemia 
(2000–274,000 parasites/μl) were selected for sequencing 
of anti-malarial drug resistance loci, including pfmdr1 
(PF3D7_0523000; including codons 86, 184 and 1246), 
pfk13 (PF3D7_1343700; including codons 417 to codon 
714), pfdhfr (PF3D7_0417200.1; including codons 50, 51, 
59, 108 and 164) and pfdhps (PF3D7_0810800.1; includ-
ing codons 431, 436, 437, 540). Genes were PCR ampli-
fied and products cleaned using SureClean (Bioline, USA) 
following manufacturer instructions. The PCR products 
were analysed by electrophoresis on a 1.5% agarose gel 
stained with GreenSafe Premium (Nzytech) to confirm 
amplification. The primer pairs and thermocycling con-
ditions are summarized in Additional file  1: Table  S1. 
The PCR products were sequenced using Sanger capil-
lary platform, and the resulting sequences were analysed 
using Geneious software (v4.8.5) and the laboratory-
adapted strain 3D7 was used as reference. A fragment 
of the pfcrt gene (PF3D7_0709000; including codons 72, 
74, 75, 76) was also examined. Three dual-labelled probes 
with sequences complementary to each of the pfcrt 72–76 
haplotypes (denoted as CVIET, CVMNK, SVMNT), were 
included in the real-time PCR reaction, each containing 
a different fluorescent molecule [15, 16]. Two amplicons 
(479 and a 516 bp) of the gene pfama1 (PF3D7_1133400) 
were amplified in 20 samples from 2017 and 4 samples 
from the 2016, using protocols published elsewhere [17]. 
Amplicons were amplified with primer pairs and ther-
mocycling conditions summarized in Additional file  1: 
Table  S1. PCR products were analysed by electrophore-
sis on a 1.5% agarose gel stained with ethidium bromide 
and sequencing using the same methodology described 
above.
Selective whole genome amplification and whole genome 
sequencing
Seven samples from 2017 with the highest parasitaemias 
(3141–126,690 parasites/μl) and meeting whole genome 
sequencing (WGS)-required DNA quality were selected 
for WGS, together with 4 samples from 2016. Genomic 
DNA was extracted from dried blood spots using the 
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QIAamp DNA Investigator Kit (QIAGEN, Germany) 
as per manufacturer’s directions. DNA concentrations 
were measured using the Invitrogen Qubit Fluorometer. 
A selective whole genome amplification (SWGA) strat-
egy was applied prior to WGS, following previously pub-
lished protocol [18]. Oligonucleotides that preferentially 
bind with high frequency to the P. falciparum DNA, and 
rarely bind to the human DNA, were used for SWGA. 
All SWGA reactions were carried out in a UV Cabinet 
for PCR Operations (UV-B-AR, Grant-Bio) to eliminate 
potential contamination. Briefly, a maximum of 60 ng of 
gDNA (minimum of 5 ng) was added to a total 50 µl reac-
tion alongside with 1X phi-29 buffer (New England Bio-
labs), 1X bovine serum albumin, 1 mM dNTPs, 2.5 µM of 
primer mix, 30 U phi-29 DNA polymerase (New England 
Biolabs) and water. The reaction was carried out on a 
thermocycler with the following step-down programme: 
5 min at 35 °C, 10 min at 34 °C, 15 min at 33 °C, 20 min at 
32 °C, 25 min at 31 °C, 16 h at 30 °C, and 10 min at 65 °C. 
The 5 samples, selected for SWGA, were then whole 
genome sequenced on a MiSeq (Illumina). The QIAseq 
FX DNA Library Kit (QIAGEN) was used for library 
preparation according to the manufacturer’s protocol, 
with a 20-min fragmentation step. Library DNA concen-
tration was analysed using a Qubit 2.0 fluorometer. All 
sequencing reactions were performed using 2 × 150  bp 
reads.
Whole genome sequence data analysis
Raw fastq files obtained after the MiSeq run were 
trimmed using trimmomatic set to default parameters 
[19], and aligned to the P. falciparum 3D7 reference 
genome (PlasmoDB) using bwa-mem software [20]. SNPs 
were identified using samtools software [21] and filtered 
for quality based on previously described methods [22, 
23]. The coverage of each nucleotide was analysed using 
sambamba [24], which was set to include SNPs with only 
a coverage of fivefold or above. To investigate the popu-
lation structure of P. falciparum parasites, a distance 
matrix was created which was based on a matrix of pair-
wise identity calculated from the SNPs present in each 
sample. Using the distance matrix, a neighbourhood-
joining tree was produced and visualized in iTOL [25]. 
WGS data from an extra 400 publicly available samples 
from Africa, South America, South Asia and Southeast 
Asia were also used for analysis [22, 23, 26]. A neighbour-
hood-joining tree was used to investigate the clustering 
of samples from West Africa.
For genetic distance comparisons between samples, a 
clustering approach using a Manhattan distance matrix 
of pair-wise identity by state values was calculated from 
the sub-set of SNPs available for each pair-wise compari-
son using the R software.
Statistical analysis
Regarding data collected by questionnaire (among other 
sociodemographic data, present and past about malaria 
and fever, travel information and signs and symptoms 
consistent with malaria), two groups were compared: 
malaria cases (n = 131) and neighbours/family members 
(n = 137).
Differences in categorical variables were tested by 
Chi-Square or Fisher exact tests. Differences in continu-
ous variables were assessed using t-tests (after check-
ing for normality and the homogeneity of variances), or 
alternatively, Mann–Whitney-Wilcoxon non-parametric 
test. Malaria cases and neighbours and family were ana-
lysed following an unmatched design, this decision was 
also supported by recent discussion about the efficiency 
of matched and unmatched studies [27, 28], balancing 
sample size and efficiency. Thus, unconditional multiple 
logistic regression models were used to to explore simul-
taneously the association of different independent vari-
ables with the binary dependent variable (malaria case 
vs close contacts), controlling for potential confounding. 
Multiple models included all variables with p < 0.20 in the 
simple logistic regression models. Adjusted odds ratios 




From the 446 cases in the 2017 outbreak, 190 blood sam-
ples collected from malaria patients before treatment 
administration, including 187 indigenous and 3 imported 
infections, were analysed. All samples were P. falciparum 
positive (PCR confirmed) and one patient presented with 
a mixed P. falciparum and Plasmodium malariae infec-
tion, undetected by microscopy. Considering indigenous 
cases group, only 27 (14.4%) were children (≤ 16 years), 
and the majority of participants were adults (n = 160, 
86.6%; range: 17–91 years old). All imported cases were 
young adults, 2 were 33 years and one 31 years of age.
Malaria cases were distributed throughout Praia city 
(Fig. 1) and consistent with official statistics. Varzea, Paiol 
and Achadinha were the neighbourhoods with highest 
number of cases (n = 13) (Fig. 1). There were no cases of 
severe malaria, nonetheless 18 patients presented with 
hyperparasitaemia (> 100,000 parasites/µl blood) ranging 
from 105,840 to 400,000 parasites/µl blood. One fatality 
was registered, but malaria was not the cause of death. 
The 3 most common self-reported symptoms in malaria 
cases were fever, headache and chills. At day 3 of hospi-
tal treatment, Giemsa-stained smears were negative for 
Plasmodium spp. for all patients. The length of hospital 
stay of malaria cases varied between 3 days to 1 month, 
with a median of 4 days (Table 1). None of the patients 
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evidenced signs of severe malaria. Extended hospitaliza-
tions were clinically justified by other medical conditions.
Sociodemographic and epidemiological characterization
Table 1 (and Additional file 1: Table S1) shows sociode-
mographic and epidemiological information of a set of 
131 patients and 137 close contacts (family members 
or neighbours, without malaria symptoms). Almost all 
participants (265/268; 98.9%) were Cape Verde nation-
als. Malaria cases were predominantly single (73.3%), 
male (65.6%) and younger than non-malaria cases (all 
p < 0.001). Malaria cases tended to travel less in the previ-
ous 6 months (5.6%) than their close contacts (11.8%), but 
this difference was marginally non-significant (p = 0.060). 
Students and tertiary-sector activities accounted for 
80.2% malaria cases and 73.0% non-malaria group. Geo-
graphical locations of the cases suggested (Fig.  1) some 
clusters in Varzea, Paiol, Achadinha, Calabaceira, and 
Pensamento, corresponding to 43.5% of all cases.
Multiple logistic regression models suggested increased 
risk of malaria from being male (OR = 4.99; 95% CI 2.90–
8.58) and single (OR = 1.92, 95% CI 1.02–3.58), with 
potentially lower risk from higher age (OR = 0.98; 95% 
CI 0.97–1.00). All malaria cases were PCR positive for P. 
falciparum, while all close contacts (n = 137) were nega-
tive. Serologic detection of P. falciparum anti-AMA1 and 
MSP-1-19 IgG/IgM was also negative for all 137 neigh-
bours and family members.
Drug resistance profile of malaria cases
A sub-set of the malaria cases (n = 38/190) was inves-
tigated for the presence of alleles associated with drug 
resistance. The chloroquine-resistant CVIET haplotype 
(pfcrt gene) was detected in all samples analysed except 
one that carried CVMNK (wild type haplotype). No 
mutations in the pfk13 gene, associated with artemisinin 
resistance, were identified. All pfk13 sequences analysed 
were identical to that of 3D7 reference strain except one 
that carried two mutations R645T and E668K, which 
have not been observed in other isolates [22]. Sulfadox-
ine-pyrimethamine (SP) drug-resistant associated alleles 
were also surveyed. For the pfdhps gene the wild-type 
haplotype (S436/A437/K540) was present in all samples 
analysed. On the other hand, for pfdhfr the triple muta-
tion S108N/N51I/C59R was detected in all analysed 
samples (n = 12). The codons 86, 184 and 1246 from the 
pfmdr1 gene were also analysed. The majority of sam-
ples (89.7%) carried the haplotype NFD (meaning N86/
F184/D1246) that is associated with artemether + lume-
fantrine tolerance and the others were wild-type for the 
3 codons (N86/Y184/D1246). No other polymorphisms 
were detected for the samples and regions analysed in the 
5 genes.
Population genetic analysis
WGS was performed in 7 autochthonous samples with 
the highest parasitaemia and 4 samples from 2016. The 
resulting data were compared to publicly available P. fal-
ciparum global genomic sequences [23, 26], in order to 
explore their genetic diversity. Prior to WGS, SWGA 
was used to increase the amount of parasite DNA. The 
success of the SWGA is very dependent on parasitae-
mia and the quality of the DNA. After WGS, the samples 
from 2016 were excluded for analysis due to having less 
than 1% of genome sequenced. The WGS data confirmed 
the drug resistance profile results, with all samples hav-
ing the pfcrt CVIET haplotype, the Y184F mutation in 
pfmdr1 gene, the triple mutation S108N/N51I/C59R in 
pfdhfr and wild type alleles for pfdhps.
A neighbour-joining tree was constructed using SNP 
data and demonstrates that the Cape Verdean samples 
group together, and cluster with samples from West 
African (Fig.  2). To investigate the genetic similarity 
between samples, an analysis of SNP sharing was per-
formed, including samples from other locations in Africa 
and Asia. The samples from Cape Verde shared > 99% 
of SNPs, while when compared with other samples on 
average 97% (maximum 97.6%) of SNPs were shared, a 
value normally observed between samples from different 
regions (e.g., African and Asian samples share on aver-
age 96.6% SNPs). To further explore the genetic diversity, 
two fragments of the PfAMA1 gene were sequenced for 
20 samples, including the samples from 2016. The results 
show that all amplified samples that were successfully 
sequenced (n = 18 for 2017; n = 3 from 2006) share the 
same haplotype in both amplicons.
Discussion
Insights into the epidemiology of Cape Verde malaria
There is a lack of studies into the genetics and epidemiol-
ogy of malaria cases in Cape Verde [2, 4]. The data con-
tradict the typical profile based on women and children 
(See figure on next page.)
Fig. 1 Number of malaria cases in Praia city per neighbourhood (N). N.1—São Filipe; N.2—Fonton; N.3—Tira Chapéu; N.4—Monte Vermelho; 
N.5—Achadinha Pires; N.6—Chã de Areia; N.7—São Pedro Latada; N.8—Bela Vista; N.27—Várzea; N.9—Achada Grande Frente; N.10—Tahiti Chã de 
Areia; N.11—Achada Eugénio Lima; N.12—Jamaica/Agua Funda; N.13—Palmarejo; N.14—Lém Cachorro; N.15—Achada Mato; N.16—Achada Santo 
António; N.17—Lém Ferreira; N.18—Ponta de Agua; N.19—Safende; N.20—Fazenda Sucupira; N.21—Vila Nova; N.22—Coqueiro Castelão; N.23—
Calabaceira; N.24—Pensamento. N.25—Paiol; N.26—Achadinha
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under-five years of age. Official data reports [2, 4] have 
indicated that more males are affected by malaria, and 
identified high-risk occupations, including construc-
tion or agricultural workers, security guards and the 
homeless. Only one agricultural worker and 4 secu-
rity guards appeared in this data, which was dominated 
by tertiary-sector activities, students and unemployed. 
The geographical pattern of the samples overlaps with 
those previous malaria hotspots, including Várzea, Chã 
de Areia, Fazenda, Achadinha Paiol, and Lém Ferreira 
neighbourhoods [2, 4]. Further, the results showed that 
all neighbours and family members tested were negative 
for malaria (serology and PCR data), which reinforces 
that infection might be occurring outside of households.
The first WGS for Cape Verdean parasites was per-
formed, and it clearly showed that the analysed samples 
cluster together and have a very high level of similarity, 
which suggests that possible the outbreak resulted from 
clonal expansion of local parasites. The Cape Verdean 
samples also cluster with isolates from West Africa, as 
expected. It would be possible to evaluate the robust-
ness of these findings by increasing the number of Cape 
Verdean parasite samples undergoing WGS, including by 
considering samples from other years.
Drug resistance associated molecular markers
Artemether + lumefantrine (AL), is the recommended 
first treatment line for uncomplicated P. falciparum 
malaria in Cape Verde [6]. Apart from therapeutic effi-
cacy studies (TES), the WHO recommends the use of 
molecular markers to monitor the emergence of muta-
tions associated with resistance to anti-malarial drugs to 
detect emerging resistance and prevent potential future 
treatment failure [29]. Anti-malarial resistance genes pol-
ymorphism were assessed by Sanger and Next Genera-
tion Sequencing (NGS), the methods were used to screen 
for mutations in a set of malaria-positive blood samples 
targeting the pfcrt, pfmdr1, pfk13, pfdhps, and pfdhfr 
genes, which have previously been associated with anti-
malarial resistance. The prevalence of the different resist-
ance alleles in Cape Verde was not known, either after or 
before the introduction of ACT in the country. The prev-
alence of pfcrt (chloroquine resistance marker)-resistant 
haplotype CVIET remains high, only one of the ana-
lysed isolates carried the wild-type haplotype CVMNK. 
Despite the implementation of ACT in Cape Verde (since 
2006) and the withdrawal of chloroquine, the frequency 
of the resistant allele 76T remains high. Although chlo-
roquine resistant pfcrt genotype prevalence follows the 
trend of continental Africa [30–32], the origin is prob-
ably different. In Cape Verde it possibly reflects the 
limited recombination opportunity, due to the very low 
malaria transmission over the recent decades. Never-
theless, the identification of the wild-type allele K76 
is in line with findings in other malaria regions, where 
AL is the predominant ACT [33–36]. Probably, due to 
lumefantrine, regimens tend to select wild-type pfcrt 
alleles [37–39]. It is generally reported that the mutant 
haplotype 51I/59R/108N in pfdhfr confers resistance 
to pyrimethamine while 437G/540E in pfdhps confers 
resistance to sulfadoxine. Combined, known as the quin-
tuple mutant, they confer resistance to SP [40–43]. For 
the pfdhps gene the wild-type (S436/A437/K540) haplo-
type was identified in all analysed samples and for pfdhfr 
the triple mutation S108N/N51I/C59R was detected also 
in all samples successfully analysed, consistent with other 
African populations, such as Malawi [22] or Senegal [44]. 
SP has never been used as first-line treatment for P. fal-
ciparum uncomplicated malaria in Cape Verde, nor has 
it ever been used as intermittent preventive treatment 
(IPT) in infants and pregnant women.
Table 1 Characteristics of the malaria patients and their close 
contacts (family and neighbours)









Age in years (Mean ± SD) 32.4 ± 15.3 40.3 ± 18.6  < 0.001
Median (Min–Max) 30 (3–86) 39 (1–83)
Gender n (%)  < 0.001
 Male 86 (65.6) 37 (27.0)
 Female 45 (34.4) 100 (73.0)
Marital status n (%)  < 0.001
 Single 96 (73.3) 66 (48.9)
 Married 12 (9.2) 25 (18.5)
 Civil union 23 (17.6) 38 (28.1)
 Divorced/widowed 0 (0.0) 6 (4.4)
Nationality n (%) 1.000
 Cape Verde 130 (99.2) 135 (98.5)
 Other 1 (0.8) 2 (1.5)
Professional status n (%) 0.150
 Unemployed 18 (13.8) 18 (13.4)
 Primary sector 1 (0.8) 0 (0.0)
 Secondary sector 5 (3.8) 11 (8.2)
 Tertiary sector 74 (56.9) 79 (59.0)
 Retired 1 (0.8) 5 (3.7)
 Student 31 (23.8) 21 (15.7)
History of malaria n (%) 1.000
 Yes 2 (1.2) 3 (2.2)
 No 129 (98.5) 133 (97.8)
Length of hospital stay in days –
Median  (P25-P75) 4 (3–4)
(Min–Max) (3–30)*
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Fig. 2 Neighbour-joining trees constructed using SNP data from Cape Verde samples using global samples. Cape Verde (pink) clusters together 
with other samples from Africa (a) particularly West Africa (b)
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The pfmdr1 amino acid mutations that have been 
implicated in multidrug-resistant phenotypes include 
N86Y, Y184F and D1246Y [45–48], where the NFD hap-
lotype is suspected to be involved in parasite tolerance 
to AL [49–51]. In this study there was high prevalence 
of the 184F (89.7%) allele as well as the NFD haplotype 
(detected in 80% of the clinical isolates analysed). The 
NFD haplotype has also been identified as the most 
commonly reported pfmdr1 haplotype in continen-
tal Africa, where AL is widely used as first-line ACT to 
treat falciparum malaria [11, 47, 52–54]. Regarding the 
pfk13, all samples were identical to 3D7 strain, only one 
sample carried 2 mutations R645T and E668K, which 
are not thought to be resistance related. This outcome 
was expected as the overall prevalence of SNPs in the 
pfk13 is reported to have low prevalence outside South-
east Asia and high diversity among African parasites [1, 
55]. The 2 SNPs identified in pfk13 gene in this study do 
not coincide either with the most reported or with the 
non-validated SNPs associated with delayed artemisinin 
parasite clearance in Africa [55, 56]. Although in Africa, 
artemisinin partial resistance has not yet been confirmed 
[1], there have been unconvincing reports of treatment 
failure in travellers returning from Africa [57, 58]. Muta-
tions in pfk13, occurring in more than one African region 
affected by malaria, are increasing [35, 59–65], evidenc-
ing the need to close monitor this gene.
The Cape Verdean population has low immunity to 
malaria, 57% live on Santiago and Boavista islands where 
local malaria transmission occurs, the rest of the popu-
lation lives in islands where no transmission occurs or 
abroad [6, 9]. Prevention measures are essential to reduce 
the risk of malaria transmission and the potential for 
malaria epidemics. Cape Verde is a country in the elimi-
nation phase of malaria, with indoor residual spraying 
with insecticides a major control strategy. This is sup-
ported by good case management with diagnostic tests 
and in-patient treatment of all cases [66]. Other actions 
recommended by the WHO are chemoprophylaxis and 
the use of mosquito nets. However, insecticide-impreg-
nated mosquito nets are less used in Cape Verde, where 
a recent study shows that only 19% of the population use 
them, but if offered them, 91% would use it [4]. There is 
the potential to reduce the rate of infection, morbidity 
and mortality, through the very cost-effective mosquito 
net malaria prevention strategy [67].
Conclusion
The majority of the parasite samples analysed shared 
the same polymorphisms in the drug resistance-asso-
ciated genes. Polymorphisms in the pfk13 gene asso-
ciated with ACT tolerance in Southeast Asia were not 
detected, but the majority of the tested samples carried 
the pfmdr1 haplotype NFD. The first WGS for Cape 
Verdean parasites was performed and showed that all 
samples cluster together, have a high level of similarity 
and are close to West African parasite populations.
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